



09/03/04

IPW

PHA 4256.12 (3481/4)  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Jaime L. Masferrer  
Serial No. 10/827,075  
Filed April 19, 2004  
Confirmation No. 1885  
For CARBONIC ANHYDRASE INHIBITOR

Art Unit 1614

September 2, 2004

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VIRGINIA 22313-1450

SIR:

**INFORMATION DISCLOSURE STATEMENT**

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicant submits copies of the references listed on the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein. In accordance with the OG notice of August 5, 2003 partially waiving the requirements of 37 C.F.R. 1.98(a)(2)(i), copies of the U.S. patent documents are not supplied.

\* Applicant submits herewith copies of the foreign patent documents and literature references.

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. §1.97(b) in that applicants believe that it is being filed prior to the mailing date of the first Office action on the merits. Accordingly, neither a statement nor fee under 37 C.F.R. §1.97(c) or (d) is required. However, if an Office action was issued prior to the date of mailing of this Information Disclosure Statement, the Commissioner is hereby authorized to charge any required fees regarding this Information Disclosure Statement to Deposit Account No. 19-1345.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Kathleen M. Petrillo".

Kathleen M. Petrillo, Reg. No. 35,076  
SENNIGER POWERS  
One Metropolitan Square, 16th Floor  
St. Louis, Missouri 63102  
(314) 231-5400

KPM/cms  
Express Mail Label No. EV 504799616 US  
Mail Stop Amendment

PTO/SB/08A

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)



|       |   |    |   |                     |                     |
|-------|---|----|---|---------------------|---------------------|
| Sheet | 1 | of | 8 | Attorney Docket No. | PHA 4256.12(3481/4) |
|-------|---|----|---|---------------------|---------------------|

*Complete if Known*

|                      |                |
|----------------------|----------------|
| Application Number   | 10/827,075     |
| Filing Date          | April 19, 2004 |
| Confirmation Number  | 1885           |
| First Named Inventor | J. Masferrer   |
| Group Art Unit       | 1614           |
| Examiner Name        |                |

## U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | U.S. Patent Document |                                      | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document<br>MM-DD-YYYY |
|--------------------|-----------------------|----------------------|--------------------------------------|---|---|
|                    |                       | Number               | Kind Code <sup>2</sup><br>(if known) |   |   |
|                    | 1                     | 4,221,783            | B1                                   | Puscas et al.                                   | 09-09-1980  |
|                    | 2                     | 5,095,026            | B1                                   | Schoenwald et al.                               | 03-10-1992  |
|                    | 3                     | 5,157,044            | B1                                   | Schoenwald et al.                               | 10-20-1992  |
|                    | 4                     | 5,416,091            |                                      | King  | 05-16-1995  |
|                    | 5                     | 5,466,823            | B1                                   | Talley et al.                                   | 11-14-1995  |
|                    | 6                     | 5,547,975            |                                      | Talley et al.                                   | 08-20-1996  |
|                    | 7                     | 5,563,165            |                                      | Talley et al.                                   | 10-08-1996  |
|                    | 8                     | 5,633,272            | B1                                   | Talley et al.                                   | 05-27-1997  |
|                    | 9                     | 5,635,172            | A                                    | Jani et al.                                     | 06/03/1997  |
|                    | 10                    | 5,691,375            | B1                                   | Behounek et al.                                 | 11-25-1997  |
|                    | 11                    | 5,760,068            | B1                                   | Talley et al.                                   | 06-02-1998  |
|                    | 12                    | 5,944,021            | B1                                   | Rodriguez                                       | 08-31-1999  |
|                    | 13                    | 5,972,684            | A                                    | Bandman et al.                                  | 10/26/1999  |
|                    | 14                    | 5,972,986            | A                                    | Seibert et al.                                  | 10/26/1999  |
|                    | 15                    | 6,025,353            | B1                                   | Masferrer et al.                                | 02-15-2000  |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

*Complete if Known*

|                      |                |
|----------------------|----------------|
| Application Number   | 10/827,075     |
| Filing Date          | April 19, 2004 |
| Confirmation Number  | 1885           |
| First Named Inventor | J. Masferrer   |
| Group Art Unit       | 1614           |
| Examiner Name        |                |

|       |   |    |   |                     |                     |
|-------|---|----|---|---------------------|---------------------|
| Sheet | 2 | of | 8 | Attorney Docket No. | PHA 4256.12(3481/4) |
|-------|---|----|---|---------------------|---------------------|

|  |    |              |    |                    |            |
|--|----|--------------|----|--------------------|------------|
|  | 16 | 6,090,834    |    | Talley et al.      | 07-18-2000 |
|  | 17 | 6,448,030    |    | Rust et al.        | 09-10-2002 |
|  | 18 | 6,465,448    |    | Gerson et al.      | 10-15-2002 |
|  | 19 | 6,664,288    |    | Pardee et al.      | 12-16-2003 |
|  | 20 | 2002/0006915 |    | Mack Strong et al. | 01-17-2002 |
|  | 21 | 2002/0035264 | A1 | Kararli et al.     | 03-21-2002 |

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document |                     |                                   | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | T <sup>6</sup> |
|--------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|--|----------------|
|                    |                       | Office                  | Number <sup>4</sup> | Kind Code <sup>2</sup> (if known) |   |  |                |
|                    | 22                    | CA                      | 2372912             | A                                 | G.D. Searle & Co.                               | 04-23-1998                                       |                |
|                    | 23                    | DE                      | 19600721            | A                                 | Hoechst AG                                      | 07-17-1997                                       |                |
|                    | 24                    | EP                      | 0826676             | A1                                | Japan Tobacco Inc.                              | 03-04-1998                                       |                |
|                    | 25                    | EP                      | 0 826 676           | A1                                | Japan Tobacco Inc.                              | 03/04/1999                                       |                |
|                    | 26                    | WO                      | 95/15316            | A1                                | G.D. Searle & Co.                               | 06-08-1995                                       |                |
|                    | 27                    | WO                      | 96/19462            | A1                                | Japan Tobacco Inc. et al.                       | 06-27-1996                                       | A              |
|                    | 28                    | WO                      | 96/25405            | A1                                | G.D. Searle & Co.                               | 08-22-1996                                       |                |
|                    | 29                    | WO                      | 97/30704            | A2                                | Merck & Co., Inc., et al.                       | 08-28-1997                                       |                |
|                    | 30                    | WO                      | 97/38986            | A1                                | G.D. Searle & Co.                               | 10-23-1997                                       |                |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

***Complete if Known***

|                      |                |
|----------------------|----------------|
| Application Number   | 10/827,075     |
| Filing Date          | April 19, 2004 |
| Confirmation Number  | 1885           |
| First Named Inventor | J. Masferrer   |
| Group Art Unit       | 1614           |
| Examiner Name        |                |

|       |   |    |   |                     |                     |
|-------|---|----|---|---------------------|---------------------|
| Sheet | 3 | of | 8 | Attorney Docket No. | PHA 4256.12(3481/4) |
|-------|---|----|---|---------------------|---------------------|

|  |    |    |           |    |                                      |            |  |
|--|----|----|-----------|----|--------------------------------------|------------|--|
|  | 31 | WO | 99/40867  | A1 | Rodriguez                            | 08-19-1999 |  |
|  | 32 | WO | 00/08024  | A  | Laboratorios S.A.L.V.A.T.            | 02-17-2000 |  |
|  | 33 | WO | 00/18741  | A  | Fuji-Sawa Pharmaceutical Co.<br>Ltd. | 04-06-2000 |  |
|  | 34 | WO | 00/23433  | A  | G.D. Searle & Co.                    | 04-27-2000 |  |
|  | 35 | WO | 00/25771  | A  | Synphora AB                          | 05-11-2000 |  |
|  | 36 | WO | 00/32189  | A1 | G.D. Searle & Co.                    | 06-08-2000 |  |
|  | 37 | WO | 01/28548  | A1 | Texas Heart Institute                | 04-26-2001 |  |
|  | 38 | WO | 01/49675  | A  | Pharmacia Corporation                | 07-12-2001 |  |
|  | 39 | WO | 01/57015  | A1 | Cayman Chemical Company, Inc.        | 08-09-2001 |  |
|  | 40 | WO | 01/90086  | A1 | Japan Tobacco Inc.                   | 11-29-2001 |  |
|  | 41 | WO | 01/91856  | A2 | Pharmacia Corporation                | 12-06-2001 |  |
|  | 42 | WO | 02/05815  | A1 | Pharmacia & Upjohn Company           | 01-24-2002 |  |
|  | 43 | WO | 02/05848  | A2 | Pharmacia Corporation                | 01-24-2002 |  |
|  | 44 | WO | 02/07731  | A2 | Sucampo AG                           | 01-31-2002 |  |
|  | 45 | WO | 02/13800  | A2 | Stefansson                           | 02-21-2002 |  |
|  | 46 | WO | 02/40052  | A1 | AGA AB                               | 05-23-2002 |  |
|  | 47 | WO | 03/013655 | A2 | Pharmacia Corporation                | 02-20-2003 |  |

**OTHER ART - NON PATENT LITERATURE DOCUMENTS**

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

|                      |                |
|----------------------|----------------|
| Application Number   | 10/827,075     |
| Filing Date          | April 19, 2004 |
| Confirmation Number  | 1885           |
| First Named Inventor | J. Masferrer   |
| Group Art Unit       | 1614           |
| Examiner Name        |                |

|       |   |    |   |                     |                     |
|-------|---|----|---|---------------------|---------------------|
| Sheet | 4 | of | 8 | Attorney Docket No. | PHA 4256.12(3481/4) |
|-------|---|----|---|---------------------|---------------------|

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.       | T <sup>6</sup> |
|--------------------|-----------------------|--|----------------|
|                    | 48                    | BRADWELL, A.R., et al., "Methazolamide Treatment of Acute Mountain Sickness," Clinical Science (London), Vol. 79, No. Supp. 23, 1990, pg. 9P, Summer Meeting of the Medical Research Society, Warwick, England, UK, July 5-6, 1990, XP008025380                      |                |
|                    | 49                    | BROOKS, D.P., et al., "Renal effects of cyclooxygenase inhibitors in volume-depleted dogs", Inflammopharmacology (2000), pp. 69-79, Vol. 8, No. 1  |                |
|                    | 50                    | CARLSEN, J., et al., "Nephrolithiasis with Dorzolamide", Archives of Ophthalmology, Aug. 1999, pp. 1087-1088, Vol. 117, No. 8, XP008025376   |                |
|                    | 51                    | CHEGWIDDEN et al., "Sulphonamide inhibitors of carbonic anhydrase inhibit the growth of human lymphoma cells in culture", Inflammopharmacology, 1995, 3(3): 231-239, XP008020859   |                |
|                    | 52                    | DALKALAS, M.C., et al., "Treatment of "Permanent" Muscle Weakness in Hypokalemic Periodic Paralysis", Neurology, April 1980, pp. 379-380, Vol. 30, No. 4, 32nd Annual Meeting of the American Academy of Neurology, New Orleans, LA, USA, May-1-3, 1980, XP008025374 |                |
|                    | 53                    | DALKALAS, M.C., et al., "Treatment of "Permanent" Muscle Weakness in Familial Hypokalemic Periodic Paralysis", Muscle & Nerve, Mar/Apr. 1983, pp. 182-186, Vol. 6, No. 3, XP008025373  |                |
|                    | 54                    | Database, WPI, Section Ch, Week 200025, Derwent Publications Ltd., London, GB; Class B03, AN 2000-293087, XP002251841 & WO 0018741A, Fujisawa Pharm Co Ltd, April 6, 2000, Abstract  |                |
|                    | 55                    | ELLIS, P.P., "Urinary Calculi With Methazolamide Therapy", Documenta Ophthalmologica, 1973, pp. 137-142, Vol. 34, No. 2, XP008025381   |                |
|                    | 56                    | FOSSLIEN, E, "Biochemistry of Cyclooxygenase(COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia", Critical Reviews in Clinical Laboratory Sciences, 2000, 37(5): 431-502, XP008020865   |                |
|                    | 57                    | GRÜNEBERG et al., "Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation", Journal of Medicinal Chem., 2002, V45, 17: 3588-3602  |                |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

|                      |                |
|----------------------|----------------|
| Application Number   | 10/827,075     |
| Filing Date          | April 19, 2004 |
| Confirmation Number  | 1885           |
| First Named Inventor | J. Masferrer   |
| Group Art Unit       | 1614           |
| Examiner Name        |                |

|       |   |    |   |                     |                     |
|-------|---|----|---|---------------------|---------------------|
| Sheet | 5 | of | 8 | Attorney Docket No. | PHA 4256.12(3481/4) |
|-------|---|----|---|---------------------|---------------------|

|    |  |  |
|----|--|--|
| 58 | GRÜNEBERG et al., "Subnanomolar Inhibitors from Computer Screening: A Model Study Using Human Carbonic Anhydrase II", Angew. Chem. Int. Ed., 2001, pp. 389-393, Vol. 40, No. 2                                   |  |
| 59 | International Search Report for application no. PCT/US/03/04469, dated September 5, 2003   |  |
| 60 | International Search Report for application no. PCT/US03/04494, dated September 29, 2003   |  |
| 61 | International Search Report for application no. PCT/US/03/04494, dated January 14, 2004  |  |
| 62 | IVANOV et al. "Down-regulation of Transmembrane Carbonic Anhydrases in Renal Cell Carcinoma Cell Lines by Wild-Type von Hippel-Lindau Transgenes", Proc. Natl. Acad. Sci. USA, 1998, pp. 12596-12601, Vol. 95.   |  |
| 63 | KALUZ et al., "Transcriptional Regulation of the MN/CA 9 Gene Coding for the Tumor-Associated Carbonic Anhydrase IX", The Journal of Biological Chemistry, 1999, pp. 32588-32595, Vol. 274, No. 46.              |  |
| 64 | KASAI et al., "Potentiation of Antitumor Activity of 1-phthalidyl 5-fluorouracil by Acetazolamide", Cancer Chemother Pharmacol, 1986, pp. 55-57, Vol 16.   |  |
| 65 | KIVELÄ et al., "Expression of a Novel Transmembrane Carbonic Anhydrase Isozyme XII in Normal Human Gut and Colorectal Tumors", American Journal of Pathology, 2000, pp. 577-584, Vol. 156, No. 2.                |  |
| 66 | MASFERRER et al., "Antiangiogenic and Antitumor Activities of Cyclooxygenase-2 Inhibitors" Cancer Research, 2000, pp. 1306-1311, Vol. 60.  |  |
| 67 | MATSUSHITA, M., et al., "Pharmacological profile of JTE-522, a novel prostaglandin H synthase-2 inhibitor, in rats, Inflammation Research", 1997, pp. 461-466, Vol. 46, No. 11, XP001176824                      |  |
| 68 | McKIERNAN et al., "The Detection of Renal Carcinoma Cells in the Peripheral Blood with an Enhanced Reverse Transcriptase-Polymerase Chain Reaction Assay for MN/CA9", Cancer, 1999, pp. 492-497, Vol. 86, No. 3. |  |
| 69 | MUDGE GH, "Diuretics and other agents employed in the mobilization of edema fluid", Gilman, A.G., L.S. Goodman and A. Gilman, 1980, 892-915, XP008009981   |  |

|                    |  |                 |
|--------------------|--|-----------------|
| Examiner Signature |  | Date Considered |
|--------------------|--|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

|                      |                |
|----------------------|----------------|
| Application Number   | 10/827,075     |
| Filing Date          | April 19, 2004 |
| Confirmation Number  | 1885           |
| First Named Inventor | J. Masferrer   |
| Group Art Unit       | 1614           |
| Examiner Name        |                |

|       |   |    |   |                     |                     |
|-------|---|----|---|---------------------|---------------------|
| Sheet | 6 | of | 8 | Attorney Docket No. | PHA 4256.12(3481/4) |
|-------|---|----|---|---------------------|---------------------|

|    |   |
|----|---|
| 70 | MURAKAMI et al., "MN/CA9 Gene Expression as a Potential Biomarker in Renal Cell Carcinoma." BJU International, 1999, pp. 743-747, Vol. 83.  |
| 71 | NÓGRÁDI et al., "The Role of Carbonic Anhydrases in Tumors", American Journal of Pathology, 1998, pp. 1-4, Vol. 153, No. 1.   |
| 72 | OWA et al., "Novel Sulphonamide Derivatives for the Treatment of Cancer", Exp. Opin. Ther. Patents, 2000, pp. 1725-1740, Vol. 10, No. 11.   |
| 73 | PARFITT et al., "Martindale, The Complete Drug Reference", Pharmaceutical Press, 1999, XP002252808  |
| 74 | PARFITT, K., "Martindale, The Complete Drug Reference, 32nd Edition", 1999, p. 778, PHARMACEUTICAL PRESS, London, UK, XP002264621   |
| 75 | PARKKILA et al., "Carbonic Anhydrase Inhibitor Suppresses Invasion of Renal Cancer Cells in vitro", PNAS, 2000, pp. 2220-2224, Vol. 97, No. 5.  |
| 76 | PASTOREKOVÁ et al., "A Novel Quasi-viral Agent, MaTu, Is a Two-Component System", Virology, 1992, pp. 620-626, Vol. 187.  |
| 77 | PENNING, T.D., et al., "Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)", Journal of Medicinal Chemistry, 1997, pp. 1347-1365, Vol. 40, No. 9, XP002114833 |
| 78 | PORCELLI, M.J., et al., "A trek to the top: A review of acute mountain sickness", Journal of the American Osteopathic Association, 1995, pp. 718-720, Vol. 95, No. 12, XP000886754  |
| 79 | PUSCAS et al., "The Carbonic Anhydrase Activation is Involved in the Chemopreventive, Antitumor Effects of Non-Steroidal Anti-Inflammatory Drugs", Experimental Oncology, 1999, pp. 121-126, Vol. 21.   |
| 80 | PUSCAS et al., "Nonsteroidal Anti-Inflammatory Drugs Activate Carbonic Anhydrase by a Direct Mechanism of Action", The Journal of Pharmacology and Experimental Therapeutics, 1996, pp. 1464-1466, Vol. 277, No. 3.   |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

***Complete if Known***

|                      |                |
|----------------------|----------------|
| Application Number   | 10/827,075     |
| Filing Date          | April 19, 2004 |
| Confirmation Number  | 1885           |
| First Named Inventor | J. Masferrer   |
| Group Art Unit       | 1614           |
| Examiner Name        |                |

|       |   |    |   |                     |                     |
|-------|---|----|---|---------------------|---------------------|
| Sheet | 7 | of | 8 | Attorney Docket No. | PHA 4256.12(3481/4) |
|-------|---|----|---|---------------------|---------------------|

|    |   |  |
|----|---|--|
| 81 | RITSCHEL, W.A., et al., "Pharmacokinetics of Acetazolamide in Healthy Volunteers after Short- and Long-Term exposure to High Altitude", Journal of Clinical Pharmacology, June 1998, pp. 533-539, Vol. 38, No. 6, XP008025379   |  |
| 82 | SAARNIO et al., "Immunohistochemical Study of Colorectal Tumors for Expression of a Novel Transmembrane Carbonic Anhydrase, MN/CA IX, with Potential Value as a Marker of Cell Proliferation", American Journal of Pathology, 1998, pp. 279-285, Vol. 153, No. 1.   |  |
| 83 | SCOZZAFAVA et al., "Carbonic Anhydrase Inhibitors: Synthesis of N-Morpholyl-thiocarbonylsulfenylamino Aromatic/Heterocyclic Sulfonamides and their Interaction with Isozymes I, II, and IV", Bioorganic & Medicinal Chemistry Letters, 2000, pp. 1117-1120, Vol. 10.  |  |
| 84 | SCOZZAFAVA et al., "Carbonic Anhydrase and Matrix Metalloproteinase Inhibitors: Sulfonylated Amino Acid Hydroxamates with MMP Inhibitory Properties Act as Efficient Inhibitors of CA Isozymes I, II, and IV, and N-Hydroxysulfonamides Inhibit both these Zinc Enzymes", Journal of Medicinal Chemistry, 2000, pp. 3677-3687, Vol. 43.   |  |
| 85 | SUPURAN et al. "Carbonic Anhydrase Inhibitors - Part 94. 1,3,4-Thiadiazole-2-Sulfonamide Derivatives as Antitumor Agents?", Eur. J. Med. Chem, 2000, pp. 867-874, Vol. 35.  |  |
| 86 | TAWIL, R., et al., "Acetazolamide-induced nephrolithiasis: Implications for treatment of neuromuscular disorders", Neurology, June 1993, pp. 1105-1106, Vol. 43, No. 6, XP008025375   |  |
| 87 | TAWIL, R., et al., "Randomized Trials of Dichlorphenamide in the Periodic Paralyses", Annals of Neurology, Jan. 2000, pp. 46-53, Vol. 47, No. 1, XP008025370  |  |
| 88 | TEICHER et al., "A Carbonic Anhydrase Inhibitor as a Potential Modulator of Cancer Therapies", Anticancer Research, 1993, pp. 1549-1556, Vol. 13  |  |
| 89 | TRICARICO, D., et al., "Effects of acetazolamide on Ca- <sup>2+</sup> activated K <sup>+</sup> channels of skeletal muscle fibers of K <sup>+</sup> depleted rats, an animal model of hypokalemic periodic paralysis", Society for Neuroscience Abstracts, 1997, p. 1482, Vol. 23, No. 1-2, 27th Annual Meeting of the Society for Neuroscience; New Orleans, LA, USA, Oct. 25-30, 1997, XP001160974, |  |
| 90 | TÜRECI et al., "Human Carbonic Anhydrase XII: cDNA Cloning, Expression, and Chromosomal Localization of a Carbonic Anhydrase Gene that is Overexpressed in Some Renal Cell Cancers", Proc. Natl. Acad. Sci. USA, 1998, pp. 7608-7613, Vol. 95.  |  |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

|            |   |    |   |                          |                     |
|------------|---|----|---|--------------------------|---------------------|
| PTO/SB/08A |   |    |   | <b>Complete if Known</b> |                     |
|            |   |    |   | Application Number       | 10/827,075          |
|            |   |    |   | Filing Date              | April 19, 2004      |
|            |   |    |   | Confirmation Number      | 1885                |
|            |   |    |   | First Named Inventor     | J. Masferrer        |
|            |   |    |   | Group Art Unit           | 1614                |
|            |   |    |   | Examiner Name            |                     |
| Sheet      | 8 | of | 8 | Attorney Docket No.      | PHA 4256.12(3481/4) |

|  |    |   |  |
|--|----|---|--|
|  | 91 | ULMASOV et al., "Purification and Kinetic Analysis of Recombinant CA XII, a Membrane Carbonic Anhydrase Overexpressed in Certain Cancers", PNAS, 2000, pp. 14212-14217, Vol. 97, No. 26.                                      |  |
|  | 92 | VERMYLEN et al. "Carbonic Anhydrase IX Antigen Differentiates Between Preneoplastic Malignant Lesions in Non-Small Cell Lung Carcinoma", Eur Respir J., 1999, pp. 806-811, Vol. 14.   |  |
|  | 93 | WAKITANI, K., et al., "JTE-552 Selectively inhibits cyclooxygenase-2-derived prostaglandin production in inflammatory tissues", Inflammation Research (2000), pp. 117-122, Vol. 49, No. 3, XP001126211                        |  |
|  | 94 | WILGUS, T.A., et al., "Topical application of a selective cyclooxygenase inhibitor suppresses UVB Vol. 62, No. 4, mediated cutaneous inflammation", Prostaglandins & Other Lipid Mediators, (2000), pp. 367-384, XP001074004, |  |
|  | 95 | WOLFENSBERGER, T., "The Role of Carbonic Anhydrase Inhibitors in the Management of Macular Edema", Documenta Ophthalmologica, 1999, pp. 387-397, Vol. 97.   |  |
|  | 96 | WYKOFF et al., "Hypoxia-inducible Expression of Tumor-Associated Carbonic Anhydrases", Cancer Research, 2000, pp. 7075-7083, Vol. 60.   |  |
|  | 97 | YOUSSEF et al., "Synthesis of certain diarylsulfonylureas as antitumor agents", Medicinal Chemistry Research, 2001, 10(6): 404-418, XP008020857   |  |
|  | 98 | ZÁVADA et al., "Human Tumor-Associated Cell Adhesion Protein MN/CA IX: Identification of M75 Epitope and of the Region Mediating Cell Adhesion", British Journal of Cancer, 2000, pp. 1808-1813, Vol. 82, No. 11.             |  |

|                    |  |                 |
|--------------------|--|-----------------|
| Examiner Signature |  | Date Considered |
|--------------------|--|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.